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The NF-kB signaling pathway is important in the regulation of physiological and malignant hematopoiesis. In
this issue of Immunity, Brechmann et al. (2012) identify a phosphatase, PP4R1, that inhibits NF-kB activation
in T cells and T cell lymphoma.The regulated expression and activation
of the transcription factor NF-kB plays a
critical role in cellular responses to
external stimuli by modulating a broad
spectrum of target genes that control
cell proliferation, differentiation, and sur-
vival (Hayden and Ghosh, 2012). To no
surprise, deregulation of NF-kB signaling
results in devastating consequences.
Aberrant NF-kB activity has been shown
to induce a wide spectrum of diseases
that include cancer, neurodegeneration,
arthritis, and atherosclerosis (Gamble
et al., 2012). In the context of immune
system, NF-kB functions as a key molec-
ular mediator in development and differ-
entiation of T lymphocytes. Stimulation
through the T cell receptor (TCR) or tumor
necrosis factor (TNF) receptor 1 (TNFR1)
leads to IkB kinase (IKK) complex medi-
ated phosphorylation and subsequent
proteasome degradation of inhibitory kB
proteins (IkBs), allowing for translocation
of NF-kB proteins to the nucleus, where
they bind to DNA and initiate transcrip-
tional machinery (Ha¨cker and Karin,
2006). It was previously shown that
several immune malignancies depend on
NF-kB activation, including multiple
myeloma, distinct lymphoma types, and
acute T cell leukemia (Lim et al., 2012).
Targeting of NF-kB is presented to be an
attractive therapeutic avenue aimed to
either inhibit tumor growth or ‘‘weaken’’
tumor cells, making them more suscep-
tible to chemotherapy. Several NF-kB
small molecule inhibitors that directly
target the IKK complex are currently
under intense investigation and have
been introduced in clinical trials (Gamble
et al., 2012).
NF-kB signaling is modulated by an
intricate network of regulatory elements.
For example, a number of kinases such594 Immunity 37, October 19, 2012 ª2012 Elas PI3K, PDk1, PKCq, TAK1, and
MEKK3 were shown to regulate NF-kB
(Ha¨cker and Karin, 2006). It is generally
believed that dephosphorylation, which
antagonizes protein phosphorylation,
plays an important role in fine-tuning of
NF-kB signaling; yet, after a couple
decades of extensive research, much
less is known about phosphatases
involved in regulating machinery of
NF-kB activation (Li et al., 2008). In this
issue of Immunity, Brechmann et al.
(2012) demonstrates that the PP4R1-
PP4c complex is an important negative
regulator of canonical NF-kB signaling in
T cells.
To identify phosphatases that modulate
NF-kB signaling, the authors performed
an RNAi screen and identified small inter-
fering RNAs (siRNAs) that enhanced
NF-kB reporter activity in Jurkat T cell
leukemia line upon TCR-CD28 or TNFR1
stimulation. One of the strongest ‘‘hits’’
of this siRNA screen was protein phos-
phatase 4, regulatory subunit 1 (PP4R1),
a noncatalytic molecule that acts as an
interaction partner of the catalytic protein
phosphatase 4 (PP4c). PP4c is a serine
-threonine phosphatase that belongs to
PP2A phosphatase family. PP4R1 is ubiq-
uitously expressed and is highly con-
served between species. In 1999, Kloeker
and Wadzinski, while looking for physio-
logical substrates of PP4c, purified the
PP4R1-PP4 heterodimer (Kloeker and
Wadzinski, 1999). Since then, a list of
PP4c-interacting partners has grown to
include several PP4R proteins (PP4R4,
PP4R2, and PP4R3), elucidating an
assortment of phosphatase complexes.
The biological function of PP4R mole-
cules began to surface only recently and
has been mainly linked to repair of DNA
double-strand breaks (Lee et al., 2010).sevier Inc.Upon examination of PP4R1 expres-
sion in T cells, the authors found that the
PP4R1 protein was undetectable in
resting cells and its expression increased
significantly upon T cell stimulation,
whereas PP4c expression remained con-
stant regardless of cell activation state.
They then showed that in expanded
human T cells, silencing of PP4R1 expres-
sion led to activation of NF-kB pathway,
whereas overexpression of PP4R1 re-
sulted in NF-kB inhibition. Subsequent to
performing a series of methodical experi-
ments, Brechmann et al. (2012) con-
cluded that PP4R1 acted as a negative
regulator of canonical NF-kB signaling in
TCR-CD28 or TNFR1-triggered T cells.
The group then hypothesized that
PP4R1 acted on a common convergent
of NF-kB signaling. Indeed, they discov-
ered that in activated T cells, PP4R1
directly interacted with IKKa and IKKb,
the enzymatic subunits of IKK complex.
The authors meticulously dissected the
mechanism of that interaction and
showed that PP4c catalytic subunit asso-
ciated with IKK only in the presence of
PP4R1. Those results indicated that
PP4R1 linked PP4c with IKK complex,
allowing its dephosphorylation and
subsequent NF-kB inhibition.
Brechmann et al. (2012) further as-
sessed a role of PP4R1 in T cell tumors.
Cutaneous T cell lymphoma (CTCL)
encompasses a heterogeneous group of
cutaneous malignancies manifested by
clonal proliferation of CD4+ T cells that
home to patients’ skin. The two most
common forms of CTCL are mycosis
fungoides, which presents in the skin
with erythematous plaques, and Se´zary
syndrome characterized by substantial
leukemic T cell burden in the blood
as well as erythroderma. Currently a
Figure 1. The PP4R1-PP4c Complex Is a Negative Regulator of NF-kB Signaling in T Cells
Signaling though TCR-CD28 or TNFR1 leads to phosphorylation of IKK complex and subsequent NF-kB activation as well as PP4R1 expression. PP4R1molecule
links IKK with phosphatase PP4c resulting in partial dephosphorylation of IKK and dampening of NF-kB activity. In T cell lymphoma, absence of PP4R1 leads to
inability of PP4c to associate and dephosphorylate the IKK complex, leading to untamed IKK phosphorylation and aberrant NF-kB activity.
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therapies is used to target both of these
CTCL forms. Despite the ongoing efforts,
however, those diseases are rarely
curable (Wong et al., 2011). Atypical NF-
kB activity has been previously implicated
to play a key role in CTCL progres-
sion. Specifically, constitutively activated
NF-kB signaling was shown to promote
resistance to apoptosis in CTCL cell lines
as well as peripheral blood lymphocytes
from patients with Se´zary syndrome.
Importantly, targeted inhibition of NF-kB
pathway in CTCL cell lines using proteo-
some 26S inhibitors, which restrained
NF-kB translocation to the nucleus, re-
sulted in decreased proliferation and cell
viability though induction of apoptosis
(Sors et al., 2006). To date, the mecha-
nisms mediating NF-kB deregulation in
CTCL remain elusive. Given the role of
PP4R1 in negative regulation of NF-kB in
T cells, Brechmann et al. (2012) examined
a relationship between NF-kB activity in
CTCL cells and PP4R1 expression. The
authors found that primary tumor cellsfromperipheral blood of Se´zary syndrome
patients as well as several CTCL cell lines
had markedly reduced expression as well
as protein amounts of PP4R1. Specifi-
cally, a CTCL cell line, HH, derived from
primary Se´zary cells, completely lacked
PP4R1 expression and displayed consti-
tutive IKKb kinase activity. To address
weather forced re-expression of PP4R1
altered the proliferation of malignant
cells, the authors retrovirally transduced
PP4R1 into CTCL cell lines. Tumor cells
that displayed expression of PP4R1 prior
to retroviral transduction were unaffected
by overexpression of PP4R1. In contrast,
CTCL cell lines, which had decreased
levels of PP4R1 or lacked it entirely
to begin with, displayed significantly
reduced cell abundance as a result of
PP4R1 overexpression. Taken together,
those studies suggest a role for PP4R1
as a suppressor of aberrant NF-kB
signaling in CTCL malignancy (see also
Figure 1).
The present work illuminates the mech-
anism of NF-kB suppression by theImmunity 37PP4R1/PP4c complex and raises a
number of questions regarding regulation
of PP4R1. Specifically, given the variety of
feedback mechanisms enveloping NF-kB
activity, it would be interesting to know
whether PP4R1 expression is modulated
by NF-kB itself. Moreover, physiological
functions of the PP4R1-PP4c complex
should be further elucidated. Also, it is
not clear whether decreased expression
of PP4R1 in CTCL cells is caused by
genetic lesions or a result of posttran-
scriptional and/or posttranslational modi-
fication. Thus, targeted exon sequencing
of PP4R1, putative PP4R1 expression
regulators, and other members of the
PP4c complex would be important to
determine whether these genes are tar-
geted in CTLC. Finally, these studies
propose further focus on PP4c complex
function in additional types of lymphomas
where previously NF-kB-specific activity
was discovered (Lim et al., 2012), espe-
cially as such enzymatic complexes could
be targeted using molecularly designed
small molecules., October 19, 2012 ª2012 Elsevier Inc. 595
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Interactions between stromal organizer cells and hematopoietic lymphoid inducer cells initiate lymph-node
formation. In this issue of Immunity, Be´ne´zech et al. demonstrate that adipocyte precursors give rise to
lymph-node stromal organizer cells, illuminating an important step in lymphoid-tissue development.Lymph nodes (LNs) serve as meeting
points for antigen-presenting cells and
lymphocytes; they are strategically dis-
tributed in the entire body to facilitate
the initiation of immune responses and
to regulate immunological memory. Un-
like other lymphoid organs, such as
the thymus, LNs are not present in all
vertebrates; built into the evolutionarily
older lymphatic system, LNs are only
found in mammals, whereas reptiles
and birds possess primordial lymph-
node-like structures (Boehm et al.,
2012). LNs are commonly referred to
as secondary lymphoid organs for dis-
tinguishing them from primary lymphoid
tissue—in which lymphocyte develop-
ment takes place—and tertiary lym-
phoid tissue, which, although anatomi-
cally and functionally equivalent to
lymph nodes, develops as a conse-
quence of enduring inflammation. Hence,
there is significant interest in gaining
a better understanding of the cellular
and molecular sequence of lymphoid-
tissue formation (Koning and Mebius,
2012).The development of LNs during
embryogenesis and postnatal periods
has been investigated in great detail (Kon-
ing and Mebius, 2012). Put in simple
terms, it proceeds as follows: a special-
ized microenvironment consisting of so-
called lymphoid-tissue organizer (LTo)
cells attracts and interacts with a partic-
ular subset of innate lymphoid cells,
termed lymphoid-tissue inducer (LTi)
cells. Although much has been learned
about the nature and activity of LTi cells
(Cherrier and Eberl, 2012), little is known
about LTo cells. This enigmatic cell type
is the focus of the Be´ne´zech et al. (2012)
paper published in this issue of Immunity.
Be´ne´zech et al. have used a clever combi-
nation of detailed cellular phenotyping,
ingenious manipulation of genetically
modified embryonic tissue grafts, and
in vitro differentiation experiments to
identify the developmental progenitors of
LTo cells. Because LNs develop in close
association with fat deposits, the authors
hypothesized that adipocytes and
lymph-node stromal cells, both of mesen-
chymal origin, might be developmentallyrelated. In support of this notion, the
analysis of cell-surface-marker profiles
revealed strong similarities between pre-
sumptive preadipocytes isolated from fat
pads and stromal cell populations present
in inguinal lymph nodes. Intriguingly,
Be´ne´zech et al. found that shared cell-
surface receptors included the lympho-
toxin b receptor (LTbR). Knowing that
signaling through LTbR is crucial for
lymph-node formation (Ruddle and
Akirav, 2009), they examined the effect
of engaging this signaling pathway in pre-
adipocytes and found that LTbR signaling
activates the alternative NF-kB signaling
pathway and thus inhibits differentiation
to mature adipocytes. As a result, preadi-
pocytes begin to express a group of
genes characteristic of LN stromal cells,
namely those encoding chemokines,
such as Cxcl13, Ccl21, and Ccl19, and
cell-adhesion molecules, such as Icam1
and Vcam1. In short, LTbR signaling
diverts preadipocytes into a cell type
resembling LTo cells. In tissue-grafting
experiments, Be´ne´zech et al. then estab-
lished that embryonic preadipocytes
